MAPT and Alzheimer disease: The following β amyloid deposition, pathologic tau, and neurodegeneration (ATN) guidelines for AD diagnosis that combine both CSF and imaging biomarkers have been proposed by the National Institute on Aging-Alzheimer’s Association [37].